<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font23 { font-size : 23; } .font24 { font-size : 24; } .font26 { font-size : 26; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font30">patients </span>
   <span class="font26">HBV </span>
   <span class="font24">hepatitis </span>
   <span class="font23">HBVr </span>
   <span class="font18">risk </span>
   <span class="font18">infection </span>
   <span class="font17">virus </span>
   <span class="font16">rheumatic </span>
   <span class="font16">chronic </span>
   <span class="font16">reactivation </span>
   <span class="font16">resolved </span>
   <span class="font15">treated </span>
   <span class="font14">antiviral </span>
   <span class="font14">treatment </span>
   <span class="font13">HBsAg </span>
   <span class="font12">data </span>
   <span class="font12">rheumatoid </span>
   <span class="font12">Clin </span>
   <span class="font12">agents </span>
   <span class="font12">immunosuppressive </span>
   <span class="font12">infection. </span>
   <span class="font12">therapy </span>
   <span class="font12">prophylaxis </span>
   <span class="font12">screening </span>
   <span class="font12">use </span>
   <span class="font12">arthritis </span>
   <span class="font12">diseases </span>
   <span class="font12">cases </span>
   <span class="font12">{border-style </span>
   <span class="font12">inhibitors </span>
   <span class="font12">studies </span>
   <span class="font12">biologic </span>
   <span class="font12">high </span>
   <span class="font12">px;} </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">DNA </span>
   <span class="font11">Rheumatol; </span>
   <span class="font11">monitoring </span>
   <span class="font11">positive </span>
   <span class="font11">receiving </span>
   <span class="font11">retrospective </span>
   <span class="font11">study </span>
   <span class="font11">surface </span>
   <span class="font11">prospective </span>
   <span class="font11">Ann </span>
   <span class="font11">anti-HBs </span>
   <span class="font11">antibody </span>
   <span class="font11">antigen; </span>
   <span class="font11">disease </span>
   <span class="font11">management </span>
   <span class="font11">viral </span>
   <span class="font11">associated </span>
   <span class="font11">cohort </span>
   <span class="font11">infection, </span>
   <span class="font11">used </span>
   <span class="font11">Dis; </span>
   <span class="font11">HBV-DNA </span>
   <span class="font11">Rheum </span>
   <span class="font11">literature </span>
   <span class="font11">low </span>
   <span class="font11">reported </span>
   <span class="font11">HBVr. </span>
   <span class="font11">Low </span>
   <span class="font11">antirheumatic </span>
   <span class="font11">clinical </span>
   <span class="font11">core </span>
   <span class="font11">patient </span>
   <span class="font11">psoriasis </span>
   <span class="font11">rate </span>
   <span class="font11">therapy. </span>
   <span class="font11">versus </span>
   <span class="font11">GCs </span>
   <span class="font11">RTX </span>
   <span class="font11">dose </span>
   <span class="font11">factors </span>
   <span class="font11">immunosuppression </span>
   <span class="font11">lower </span>
   <span class="font11">patients, </span>
   <span class="font11">potential </span>
   <span class="font11">prophylactic </span>
   <span class="font11">rates </span>
   <span class="font11">study. </span>
   <span class="font11">ABA </span>
   <span class="font11">HBsAg, </span>
   <span class="font11">Hepatitis </span>
   <span class="font11">Hepatology; </span>
   <span class="font11">Moderate </span>
   <span class="font11">al.Hepatitis </span>
   <span class="font11">approved </span>
   <span class="font11">baseline </span>
   <span class="font11">disease-modifying </span>
   <span class="font11">especially </span>
   <span class="font11">immune </span>
   <span class="font11">liver </span>
   <span class="font11">necrosis </span>
   <span class="font11">need </span>
   <span class="font11">review </span>
   <span class="font11">safety </span>
   <span class="font11">solid </span>
   <span class="font11">undergoing </span>
   <span class="font10">ALT, </span>
   <span class="font10">analysis </span>
   <span class="font10">antigen </span>
   <span class="font10">appropriate </span>
   <span class="font10">case </span>
   <span class="font10">considered </span>
   <span class="font10">data, </span>
   <span class="font10">drug </span>
   <span class="font10">increased </span>
   <span class="font10">patients. </span>
   <span class="font10">prophylaxis, </span>
   <span class="font10">px; </span>
   <span class="font10">recent </span>
   <span class="font10">setting </span>
   <span class="font10">vaccine </span>
   <span class="font10">{font-family </span>
   <span class="font10">(.%) </span>
   <span class="font10">HBsAg-positive </span>
   <span class="font10">JAK </span>
   <span class="font10">Patients </span>
   <span class="font10">agents, </span>
   <span class="font10">al.A </span>
   <span class="font10">al.Safety </span>
   <span class="font10">anti-HBc, </span>
   <span class="font10">colleagues </span>
   <span class="font10">conventional </span>
   <span class="font10">cytotoxic </span>
   <span class="font10">did </span>
   <span class="font10">diseases. </span>
   <span class="font10">drugs </span>
   <span class="font10">duration </span>
   <span class="font10">factor </span>
   <span class="font10">font-size </span>
   <span class="font10">identified </span>
   <span class="font10">lamivudine </span>
   <span class="font10">majority </span>
   <span class="font10">oral </span>
   <span class="font10">prednisone </span>
   <span class="font10">prevalence </span>
   <span class="font10">psoriatic </span>
   <span class="font10">received </span>
   <span class="font10">similar </span>
   <span class="font10">systemic </span>
   <span class="font10">targeted </span>
   <span class="font10">treatment, </span>
   <span class="font10">treatment. </span>
   <span class="font10">(HBV) </span>
   <span class="font10">Arthritis </span>
   <span class="font10">MMF </span>
   <span class="font10">according </span>
   <span class="font10">al.Reactivation </span>
   <span class="font10">and, </span>
   <span class="font10">antivirals </span>
   <span class="font10">available </span>
   <span class="font10">biological </span>
   <span class="font10">chronically </span>
   <span class="font10">combination </span>
   <span class="font10">compared </span>
   <span class="font10">currently </span>
   <span class="font10">detectable </span>
   <span class="font10">different </span>
   <span class="font10">doses </span>
   <span class="font10">double; </span>
   <span class="font10">hematologic </span>
   <span class="font10">higher </span>
   <span class="font10">incidence </span>
   <span class="font10">inflammatory </span>
   <span class="font10">levels </span>
   <span class="font10">monoclonal </span>
   <span class="font10">negative/anti-HBc </span>
   <span class="font10">past </span>
   <span class="font10">prednisolone </span>
   <span class="font10">published </span>
   <span class="font10">relevant </span>
   <span class="font10">replication </span>
   <span class="font10">reports </span>
   <span class="font10">serum </span>
   <span class="font10">status </span>
   <span class="font10">synthetic </span>
   <span class="font10">tumor </span>
   <span class="font10">usually </span>
   <span class="font10">(%) </span>
   <span class="font10">(/) </span>
   <span class="font10">B-cell </span>
   <span class="font10">CYC </span>
   <span class="font10">Figure </span>
   <span class="font10">However, </span>
   <span class="font10">IL- </span>
   <span class="font10">Res; </span>
   <span class="font10">Rev </span>
   <span class="font10">TNF </span>
   <span class="font10">TNFi </span>
   <span class="font10">Table </span>
   <span class="font10">antibodies </span>
   <span class="font10">arthritis, </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">carriers </span>
   <span class="font10">chemotherapy. </span>
   <span class="font10">complication </span>
   <span class="font10">csDMARD </span>
   <span class="font10">daily </span>
   <span class="font10">disease, </span>
   <span class="font10">diseases, </span>
   <span class="font10">effect </span>
   <span class="font10">efficacy </span>
   <span class="font10">evidence </span>
   <span class="font10">following </span>
   <span class="font10">immunosuppressives </span>
   <span class="font10">inhibitor </span>
   <span class="font10">large </span>
   <span class="font10">load </span>
   <span class="font10">long-term </span>
   <span class="font10">lymphoma </span>
   <span class="font10">markers </span>
   <span class="font10">medical </span>
   <span class="font10">meta-analysis </span>
   <span class="font10">moderate </span>
   <span class="font10">mofetil </span>
   <span class="font10">monitoring, </span>
   <span class="font10">multicenter </span>
   <span class="font10">novel </span>
   <span class="font10">occult </span>
   <span class="font10">receive </span>
   <span class="font10">recently </span>
   <span class="font10">results </span>
   <span class="font10">rituximab </span>
   <span class="font10">severe </span>
   <span class="font10">showing </span>
   <span class="font10">solid; </span>
   <span class="font10">strategy </span>
   <span class="font10">studied </span>
   <span class="font10">support </span>
   <span class="font10">time </span>
   <span class="font10">tocilizumab </span>
   <span class="font10">vaccination </span>
   <span class="font10">virological </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(Figure </span>
   <span class="font10">(HBsAg) </span>
   <span class="font10">(Table </span>
   <span class="font10">(i.e. </span>
   <span class="font10">(−) </span>
   <span class="font10">ALT </span>
   <span class="font10">Association </span>
   <span class="font10">Care </span>
   <span class="font10">Chronic </span>
   <span class="font10">Dermatol; </span>
   <span class="font10">Drug </span>
   <span class="font10">Epub </span>
   <span class="font10">Gastroenterology; </span>
   <span class="font10">HBV, </span>
   <span class="font10">HBV-DNA, </span>
   <span class="font10">HBV-infected </span>
   <span class="font10">HBsAg-negative </span>
   <span class="font10">Int </span>
   <span class="font10">MTX </span>
   <span class="font10">Med; </span>
   <span class="font10">Oncol; </span>
   <span class="font10">Taiwanese </span>
   <span class="font10">Ther; </span>
   <span class="font10">United </span>
   <span class="font10">acute </span>
   <span class="font10">advice </span>
   <span class="font10">agent </span>
   <span class="font10">ahead </span>
   <span class="font10">al.Prevalence </span>
   <span class="font10">al.Risk </span>
   <span class="font10">al.The </span>
   <span class="font10">alanine </span>
   <span class="font10">aminotransferase; </span>
   <span class="font10">anti-HBc </span>
   <span class="font10">arthritis. </span>
   <span class="font10">barrier </span>
   <span class="font10">based </span>
   <span class="font10">believe </span>
   <span class="font10">biochemical </span>
   <span class="font10">biologics </span>
   <span class="font10">bold </span>
   <span class="font10">chemotherapy </span>
   <span class="font10">close </span>
   <span class="font10">commencing </span>
   <span class="font10">contrary, </span>
   <span class="font10">corticosteroid </span>
   <span class="font10">courier; </span>
   <span class="font10">described </span>
   <span class="font10">developed </span>
   <span class="font10">diseases: </span>
   <span class="font10">does </span>
   <span class="font10">drugs. </span>
   <span class="font10">em; </span>
   <span class="font10">experience </span>
   <span class="font10">flare </span>
   <span class="font10">genetic </span>
   <span class="font10">geographical </span>
   <span class="font10">having </span>
   <span class="font10">hepatic </span>
   <span class="font10">host’s </span>
   <span class="font10">inactive </span>
   <span class="font10">including </span>
   <span class="font10">infected </span>
   <span class="font10">infection: </span>
   <span class="font10">inhibition </span>
   <span class="font10">looking </span>
   <span class="font10">mycophenolate </span>
   <span class="font10">new </span>
   <span class="font10">period </span>
   <span class="font10">pooled </span>
   <span class="font10">presence </span>
   <span class="font10">prevention </span>
   <span class="font10">print </span>
   <span class="font10">prior </span>
   <span class="font10">pt;} </span>
   <span class="font10">receptor </span>
   <span class="font10">secukinumab </span>
   <span class="font10">short </span>
   <span class="font10">significant </span>
   <span class="font10">significantly </span>
   <span class="font10">study, </span>
   <span class="font10">systematic </span>
   <span class="font10">tenofovir </span>
   <span class="font10">thus, </span>
   <span class="font10">titers </span>
   <span class="font10">trial </span>
   <span class="font10">trials </span>
   <span class="font10">used. </span>
   <span class="font10">various </span>
   <span class="font10">virus. </span>
   <span class="font10">virus; </span>
  </p>
 </body>
</html>
